Description

Balversa (Erdafitinib) – Targeted Therapy for Advanced Urothelial Cancer

Precision Treatment for FGFR-Driven Cancer

Balversa (erdafitinib) is an oral targeted therapy designed for adults with locally advanced or metastatic urothelial carcinoma (bladder cancer) that has specific FGFR2 or FGFR3 genetic alterations and has progressed during or after platinum-containing chemotherapy.

It belongs to a class of medicines called FGFR kinase inhibitors, which work by blocking abnormal signals that help cancer cells grow.

---

How Balversa Works

Cancer cells with FGFR gene alterations can grow and divide uncontrollably.
Balversa targets and inhibits fibroblast growth factor receptors (FGFRs), helping to:

• Slow or stop tumor growth
• Reduce cancer cell survival
• Address cancer driven by genetic mutations rather than location alone

---

Indications

Balversa is indicated for:

• Adults with locally advanced or metastatic urothelial carcinoma
• Tumors with susceptible FGFR3 or FGFR2 genetic alterations
• Disease progression after platinum-based chemotherapy

---

Key Benefits

• Oral, once-daily targeted therapy
• Designed for genetically selected patients
• Personalized oncology approach
• Offers an option after chemotherapy failure

---

Dosage & Administration

• Taken orally once daily
• Dose may be adjusted based on blood phosphate levels and tolerance
• Treatment should be guided by a qualified oncologist
• Regular monitoring of eye health and blood chemistry is required

---

Important Safety Information

Balversa may cause side effects. Patients should be closely monitored for:

• Eye disorders (dry eye, blurred vision, central serous retinopathy)
• High phosphate levels (hyperphosphatemia)
• Skin and nail changes
• Fatigue, diarrhea, or decreased appetite

Eye examinations are recommended prior to and during treatment.

---

Who Should Not Use Balversa

Balversa may not be suitable for individuals who:

• Do not have confirmed FGFR2/FGFR3 genetic alterations
• Are pregnant or planning pregnancy
• Have uncontrolled medical conditions without medical supervision

---

Monitoring During Treatment

Patients on Balversa should undergo regular:

• Blood phosphate level checks
• Eye examinations by an ophthalmologist
• Kidney and liver function tests
• Response evaluation through imaging scans

---

Talk to Your Oncologist

Treatment decisions for Balversa should always be based on genetic testing and specialist evaluation. A medical oncologist can determine whether this therapy is appropriate for your condition.

---

About Balversa

Balversa (erdafitinib) is part of a new generation of precision oncology treatments that target cancer at the molecular level, offering hope for patients with specific genetic cancer drivers.

---